Metabolic Syndrome Disorders In Urban Black Zimbabweans With Type 2 Diabetes Mellitus by Makuyana, D et al.
THE CENTRAL AFRICAN 
JOURNAL OF MEDICINE
ORIGINAL ARTICLES
Metabolic syndrome disorders in urban black Zimbabweans with
type 2 Diabetes mellitus
*D MAKUYANA, * *ZAR GOMO, ***T MUNYOMBWE, ****JA MATENGA, ****JG HAKIM
Abstract
Objective: The main aim of the study was to determine the prevalence of metabolic syndrome disorders and 
their interrelations in black Zimbabwean type 2 diabetic patients.
Study Design: Prospective cross sectional study.
Setting: Outpatient diabetic clinics at Harare and Parirenyatwa tertiary hospitals.
Main Outcome Measures: We recruited 109 adult diabetic subjects attending a tertiary hospital Diabetic 
Clinic. Anthropometric and metabolic parameters were measured by standard methods. Eighty percent of the 
patients were hypertensive, 32% dyslipidaemic, 32% obese, 50% hyperinsulinaemic, 61% had poor 
• glycaemic control and 43% of the participants had the metabolic syndrome. The means of BMI and 
triglycerides were significantly different in hyperinsulinaemic versus non-hyperinsulinaemic patients 
(p<0.001 and 0.041 respectively), and diastolic blood pressure was significantly raised in the obese group 
(p=0.043).
The following significant associations were observed, hyperinsulinaemia with the metabolic syndrome (odds 
ratio=3.9, p<0.001) as well with obesity (odds ratio=4.8, p<0.001), however, only a weak association was 
observed between hypertension and hyperinsulinaemia (odds ratio=2.5, p=0.064). Patients exhibiting three 
metabolic disorders (dyslipidaemia, hypertension and obesity) were five times more likely to be 
hyperinsulinaemic (p=0.025) and hypertensive patients were almost three times more likely to, be 
hyperinsulinaemic.
Conclusion: In comparison to their counterparts from certain ethnic groups, this urban diabetic population 
is also burdened with a variety of metabolic disorders which are risk factors for coronary artery disease. In 
this population, hyperinsulinaemia has a relatively weak association with hypertension and the relationship 
between obesity versus diastolic blood pressure as well as hypertriglyceridaemia versus serum insulin levels 
requires further investigation.
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Introduction
Several studies have suggested a possible link between 
hyperinsulinaemia, dyslipidaemia, obesity, hypertension, 
and abnormal glucose metabolism.12 These disorders are 
common in the metabolic syndrome also known as the 
insulin resistance syndrome (IRS). According to the WHO 
definition of the metabolic syndrome, patients with type 2 
Diabetes mellitus and are insulin resistant, have the 
syndrome if they fulfill two or more of the following 
criteria: are hypertensive, have dyslipidaemia, have obesity/ 
abdominal obesity and have microalbuminuria.3 However, 
there is limited information available about the prevalence 
of the metabolic syndrome in various ethnic populations, 
and considerable controversy exists about the exact 
abnormalities that are part of the syndrome.4'5
Some epidemiological studies confirm that the metabolic 
disorders occur commonly in certain ethnic groups with 
type 2 Diabetes mellitus including Afro-Americans, 
Mexican-Americans, Australian-Aborigines, Asians and 
Europids 6'7 Zimbabwe has a population that is in transition 
from a phase of parasitic and infectious diseases to that of 
cardiovascular and degenerative diseases, due to 
urbanisation, development and change in dietary habits. It 
follows that the prevalence of Diabetes mellitus, especially 
type 2 Diabetes mellitus is on the increase and will afflict 
a significant percentage of our population. It is, therefore, 
imperative to know the patterns of metabolic aberrations 
inherent in our type 2 diabetic population.
Insulin resistance is characterised by impaired insulin- 
mediated glucose uptake, which provokes a compensatory 
increase in pancreatic beta-cell secretory activity, resulting 
in hyperinsulinaemia and hyperglycaemia. Thus insulin 
resistance may be a fundamental aspect of the aetiology of 
type 2 Diabetes mellitus, and fasting insulin levels can be 
used as a reasonable surrogate for insulin resistance in type 
2 diabetic subjects. There is some evidence that the 
combination of insulin resistance and compensatory 
hyperinsulinaemia predisposes the development of the 
cluster of abnormalities which include glucose intolerance, 
dyslipidaemia and high blood pressure.8,9 However, there 
is little information from the literature to predict if 
endogenous insulin concentrations are responsible for the 
development of these metabolic disorders. A number of 
studies have confirmed that hyperinsulinaemia is associated 
with hypertension, although this remains a controversial 
area.10,11 Blood insulin levels are a relatively weakpredictor 
of the development of hypertension in black Americans 
and a high proportion of black type 2 diabetic patients have 
been found to be insulin sensitive.12,13 Also a large number 
of Pima Indians are afflicted with hyperinsulinaemia, but 
exhibit low rates of hypertension.14 It is possible that blood 
insulin expresses itself differently in diverse ethnic groups 
and this could indicate genetic as well as environmental 
variation.15,16
The main lipid disorder in the metabolic syndrome is 
thought to arise from abnormalities in triglycerides 
metabolism. Hypertriglyceridaemia and hypo-HDL-
cholesterolaemia are the most common lipid abnormalities 
in type2diabetessubjects.Thelevels of tissue triglycerides 
determine the degree of insulin resistance and insulin 
production.17,18 Despite the fact that African-Americans 
are at a higher risk of developing cardiovascular 
complications than whites or Hispanics in the presence of 
type 2 diabetes, they have lower blood triglycerides levels 
and low HDL-cholpsterol is less common.19 The low levels 
of triglycerides may have considerable effect on insulin 
sensitivity in this ethnic population and this suggests that 
other adverse effects contribute to the heightened 
cardiovascular risk in African-Americans.
Obesity has been found to be associated with reduced 
insulin sensitivity and high fasting levels and post prandial 
blood insulin concentrations. Weight is the only factor 
with a consistent positive association with insulin levels.211
Over the last few years, there have been suggestions that 
metabolic syndrome disorders are aetiological factors for 
cardiovascular disease.20’22 However, it is not clear, which 
of the components are primary despite the fact that in 
subjects exposed to a Western lifestyle, insulin resistance 
is thought to be the common denominator. Before strategies 
of prevention and/or management of the cardiovascular 
complications are explored, it is crucial to know the extent 
of the metabolic disorders in our urban diabetic population, 
that has undergone a substantial socio-economic transition. 
Thus the main objective of this study was to establish the 
prevalence of the disorders (components) of the metabolic 
syndrome and their interrelations in urban black 
Zimbabwean type 2 diabetic patients.
Materials and Methods
Subjects.
Adult diabetics at a tertiary hospital Diabetic Clinic were 
eligible to participate in the study. Young diabetics were 
not eligible in order to avoid patients with MOD Y (maturity- 
onset diabetes of the young), a subphenotype of type 2 
Diabetes mellitus. Type 2 diabetes was defined according 
to the World Health Organization (WHO) criteria in terms 
of resistance to insulin action and inadequate compensatory 
insulin secretory response.23 All patients who were 
undergoing a combination of diet and/or oral hypoglycaemic 
treatment for type 2 Diabetes mellitus and gave their 
informed consent were recruited into the study. The study 
was approved by the local Ethics Committee. 
Anthropometric, Blood Pressure Measurements and 
Laboratory Analyses.
The history of each participant was obtained at enrolment 
using a standardised data form. Fasting venous blood was 
withdrawn from the participants and each sample was 
delivered into a potassium oxalate/sodium fluoride vial for 
fasting glucose analysis, an EDTA vial for HbAlc and a 
plain tube for other assays. The samples were sent to the 
laboratory for separation of plasma or serum.
Plasma glucose concentration was determined,on the 
Beckman CX5 Synchron analyzer by the hexosekinase
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method. Fasting levels of plasma insulin were carried out 
in an Abbott Laboratories IMX analyzer using the Abbott 
insulin microparticle enzyme immuhoassay (MEIA), which 
has no cross-reactivity with proinsulin. GLYCO-Tek 
Affinity Chromatography kits from Helena laboratories 
(Beaumont, Texas) were used to measure the blood levels 
of HbAlc The method quantitates all glycated haemoglobin 
including the A le fraction and has a between run precision 
of 6.8%. Serum triglycerides, cholesterol and HDL-C 
(direct HDL-C method) assays were carried out on the 
Cobas Mira Plus autoanalyzer using Boehringer Mannheim 
kits by enzymatic determination. The above assays except 
for HbAlc were carried out at 37°C.
Height was measured to the nearest 0.1 cm usinjj? a 
stadiometer with a right angle and weight measurements 
up to the nearest 0.1 kg were done on a calibrated scale. The 
BMI was calculated from these parameters (weight in kg' 
divided by height in metres squared). Blood pressure was 
measured in the sitting position using a mercury 
sphygmomanometer after afiveminute rest. Disappearance 
of Korotkoff sounds (phase V) was taken as the diastolic 
blood pressure. Two readings were taken at one and a half 
minute intervals and the second readingused in the statistical 
analyses.
Patient Classification.
The participants were classified as;
i) Obese if their BMI was equal or greater than 
30 Kg/m2.
ii) Hypertensive if the SBP was greater than 140 mm Hg 
and/or the DBP was greater, than 90 mm Hg or if they 
were on treatment for hypertension.
iii) Hyperinsulinaemic if the plasma insulin levels were 
above 9..2 pU/ml
iv) Dyslipidaemic if the serum triglyceride levels were 
above 2.3 mmol/L or serum HDL-cholesterol was 
below 0:9 mmol/L or both.
Statistics.
The results for continuous data are given as mean ± 
standard deviation. The students ’ two tailed t-test was used 
for continuous variables, Chi-square test and analysis for 
categorical variables. To investigate the association of the 
metabolic disorders and other variables, we used binary 
logistic regression. The statistical packages were WHO 
Epi-Info version 6 and SPSS version 10. The level of 
statistical significance was set at a p value less than 0.05.
Results
The characteristics of the study population are presented 
in Table I. The study population comprised 109 urban 
black type 2 female (n=77) and male (n=32) diabetics aged 
between 36 and 78 years. There were no significant gender 
differences in age, duration of diabetes, SBP, DBP, fasting 
plasma glucose, H bA lc, plasma insulin, HDL-C, 
cholesterol and triglyceride levels. The only significant 
gender difference was a higher BMI of 25.7 versus 28.2 
(p=0.044) for men and women respectively. The main
effects of gender, age and duration of diabetes on obesity 
(represented by BMI) were not significant using binary 
logistic regression, p>0.05. The prevalence of various 
metabolic syndrome components in the 109 type 2Diabetes 
meUitus patients are given in Table II.
Table I: Baseline characteristics of 109 type 2 Diabetes 
mellitus patients.
C h a ra c te r is t ic
M en
m e a n ± S D (n = 3 2 )
W o m e n  J  
m e a n ± S D (n = 7 7 ) p -v a lu e
A ge  (years) 5 5 - 9 55± 9 0 .902
D ura tion#  (years) 4 .2± 4 .0 5 .3 + 4 .5 0 .224
B M I* (Kg/m 2) 2 5 .7 -4 .6 28 .2± 6 .2 0 .044
S B P * (m mHg) 151±24 153±25 0 .758
D B P * (m mHg) 94± 14 9 3 ± 1 1 0 .769
P lasm a g lucose  (m m ol/L) 9 .7± 5 .6 11.2± 5.9 0 .234
H b \ * ( % ) 10.2± 3.6 10 .0± 2 .9 0 .794
P lasm a insu lin  (FU /m l) 1 1 .3 -8 .9 13 .4± 12 .0 0 .663
H D L-C * (m m ol/L) 1 .25± 0.49 1.35± 0.48 0 .649
T rig lyce ride  (m m ol/L) 1 .68± 1 .10 1 .6 1 -0 .8 6 0.748
C ho les te ro l (m m ol/L) 5 .3 + 1 .4 5 .6 -1 .4 0 .658
# Duration of diabetes.
*  BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic
blood pressure; HbAlc haemoglobin A1c; HDL-C, high density lipoprotein
cholesterol.
The significant relationships between the various
components of the metabolic syndrome in our study
population are shown in Table III. The means of insulin
were significantly different in those patients who were
obese (pcO.OOl), hypertriglyceridaemic (p=0.049), and
who had the metabolic syndrome (p=0.018). Those patients
that were hyperinsulinaemic and hypertensive had
significantly  elevated BMI (p<0001 and 0.015
respectively). The means of DBP were significantly
different in the obese diabetics compared to the non-obese
(p=0.043).
Table II: Prevalence of metabolic syndrome components in
type 2 Diabetes mellitus patients (n=7(99).
M e ta b o lic  C o m p o n e n t P r e v a le n c e  (% )
H ypertens ion  (n=87) 80
D ys ilp idaem ia * (n=35) 32
H ypo-H D L-C ** (n=26) 24
H yp e rtrig lyce ridaem ia  (n=20) 20
O besity  (n=35) 32
H ype rinsu linaem ia  (n=54) 50
M etabo lic  synd rom e  (n=47) 43
3 risk fa c to rs ***  (n=11) 10
2 risk fa c to rs ** (n=37) 34
1 risk  fa c to r**  (n=52) 48
* Serum triglyceride levels above 2.3 mmol/L or serum HDL-cholesterol 
was below 0.9
** Hypo—HDL-C, hypo-high density lipoprotein cholestrol.
*** The risk factors are obesity, hypertension and dysilpidaemia.
Table IV shows the associations between various 
metabolic syndrome components. The metabolic syndrome 
was associated with hyperinsulinaemia (pcO.001).
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H ypertension was weakly associated with 
hyperinsulinaemia, p=0.064 and obesity was associated 
with hyperinsulinaemia, pcO.OOOl. A patient who had 
three risk factors was associated with high plasma levels of 
insulin (p=0.025).
Table 111: Means of measured variables compared to 
metabolic disorders in type 2 diabetic patients (n=109).
V a r ia b le  v s  M e ta b o lic  D is o rd e r  (n *)
V a r ia b le  m ean  
(± S D )** p  v a lu e
B M I*** leve ls  vs h yp e rin su lin ae m ia  (n=54) 30 (6) vs 25  (5) <0.001
BMI leve ls  vs  h ype rtens ion  (n=87) 28 (6) vs 25  (5) 0.015
D BP  vs  o b e s ity  (n=35) 97 (10) vs 92  (13) 0.043
T rig ly ce ride  leve ls  vs  hyp e rin su lin ae m ia
(n=54) 1.81 (0.95) vs  1.46 (0.90) 0.049
Insu lin  leve ls  vs  o b e s ity  (n=35) 15.7 (9.2) vs 11.4 (11.8) <0.001
Insu lin  leve ls  vs  h yp e rtrig ly ce rida e m ia
(n= 20 )- 17.7 (14.4) vs 11.7 (10.1) 0.041
Insu lin  leve ls  vs m e tabo lic  synd rom e
(n =47) 15.6 (11.0) vs 10.6 (10.9) 0.018
*  n, is the number of patients afflicted by a metabolic disorder.
** Means and SD of variables in those patients that have the metabolic
disorder versus those where it's absent.
*** BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic
blood pressure; lipoprotein cholesterol.
Table IV: Associations o f metabolic disorders in type 2
Diabetes mellitus.
95%
O d d s C o n fid e n c e
M e ta b o lic  c o m p o n e n ts R a tio L im its p  -v a lu e
O bes ity  vs h yp e rin su lin ae m ia  x 4.8 .1 .78-12 .94 <0.0001
H ypertens ion  vs  hyp e rin su lin ae m ia 2.5 0 .84-7 .72 0 .064
O bes ity  vs DBP 2.2 0 .90-5 .33 0.061
H yp e rin su lin ae m ia  vs  m e tabo lic  synd rom e 3 .9 1.60-9.51 <0.001
H yp e rtr ig h yp o H D L -C * v s  3  ris k  fa c to rs 7.4 1 .39-40.00 0 .013
3 risk  fa c to rs  vs hyp e rin su lin ae m ia 5.3 0 .98-38.12 0.025
*  hypertrighypo-HDL-C, hypertriglyceridaemia and hypo-high density 
lipoprotein cholesterol.
Discussion
Our results clearly demonstrate that the metabolic 
syndrome, characterised by obesity, hypertension and 
dyslipidaemia is common in urban black type 2 diabetic 
patients, just as in their Caucasian counterparts. The most 
prevalent disorder was hypertension which was found in 
80% of the patients. The high prevalence of hypertension 
in these type 2 diabetic patients is bound to increase the risk 
of the development of diabetic nephropathy. Although a 
strong association between insulin resistance and 
hypertension in lean rather than obese subjects has been 
reported,24,25 this relationship remains the most controversial 
part of the m etabolic syndrom e.16'26'27 Our study 
dem onstrated a weak association between 
hyperinsulinaemia and hypertension. Since a sizeable 
number of. the study population was obese, this could
explain the weaker association between blood pressure 
and insulin levels compared to other metabolic disorders. 
Alternatively, the weak relationship could be explained by 
ethnic differences.
A clustering of metabolic disorders is a characteristic 
finding in individuals with insulin resistance, as reported 
in several studies.2lS'3u In our study 50% of the diabetic 
patients were hyperinsulinaemic and a strong significant 
association was demonstrated between hyperinsulinaemia 
and the metabolic syndrome. A subject who had high 
levels of fasting plasma insulin was three times more likely 
to be hypertensive, almost four times more likely to have 
the metabolic syndrome, and five times more likely to be 
" obese or to have three metabolic disorders.
It must be pointed out that there is little information from 
the literature to predict if endogenous insulin concentrations 
are responsible for the development of these metabolic 
disorders.
In this study, as in some studies, we confirmed that 
hypertriglyceridaemic patients have elevated fasting insulin 
levels.31-32 The blending of hypertriglyceridaemia and 
hypoHDL-cholesterolaemia has been found to be a 
particularly potent risk factor for coronary heart 
disease.31,33'34 Our study demonstrated that a subject who 
has hypertriglyceridaemia combined with low levels of 
HDL-C is about seven times more likely to have three 
metabolic risk factors. The three independent risk factors, 
obesity, hypertension or dyslipidaemia are related to 
atherosclerosis and the widespread hyperinsulinaemia and 
poor glycaemic control present in this population could 
result in accelerated atherogenesis.
Hyperinsulinaemia had a consistent positive relation 
with all the weight indices and obesity was a strong 
predictor of fasting hyperinsulinaem ia. The 
hyperinsulinaemia in these patients could be explained by 
an increase in android fat. Weight indices were associated 
with dyslipidaemia, hypertension, hyperglycaemia, and 
hyperinsulinaem ia, suggesting that obesity is a 
heterogeneous condition. Thus anthropometric measures 
can be used as indicators of the probability of dyslipidaemia, 
high blood pressure and hyperinsulinaemia in type 2 
Diabetes mellitus.
Hypertension, poor glycaem ic control, 
hyperinsulinaemia, obesity and dyslipidaemia seem to be 
a major health burden in type 2 Diabetes mellitus patients 
in this population. In our study, the clustering of obesity, 
hypertension and dyslipidaemia was associated with 
hyperinsulinaemia and it appears that hyperinsulinaemia 
has the potential to explain at least two of these metabolic 
disorders, i.e. obesity and hypertriglyceridaemia. Although 
the association between hyperinsulinaem ia and 
hypertension remains somewhat controversial, it is possible 
that it is weaker in blacks.
Inconclusion, the metabolic syndrome is common in this 
diabetic population and the constellation of the metabolic 
disorders may expose them to coronary artery disease as 
well as to the severe microvascular complications of
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diabetes. A.longitudinal study to investigate the effects of
the multitudinous metabolic disorders in these patients is
warranted. -
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